Loading…
Theriva Biologics, Inc. is projected to decline to $0.2177 by 2027, a -2% move from its current price of $0.2227. TOVX is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $0.2149 | $0.2227 | $0.2309 | +0.01% |
| Aug 6 | $0.2117 | $0.2227 | $0.2344 | +0.02% |
| Aug 7 | $0.2093 | $0.2228 | $0.2371 | +0.03% |
| Aug 8 | $0.2073 | $0.2228 | $0.2394 | +0.04% |
| Aug 9 | $0.2056 | $0.2228 | $0.2415 | +0.06% |
| Aug 10 | $0.204 | $0.2228 | $0.2434 | +0.07% |
| Aug 11 | $0.2026 | $0.2229 | $0.2451 | +0.08% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.2026 | $0.2229 | $0.2451 | +0.08% |
| Week 2 | $0.1949 | $0.223 | $0.2552 | +0.16% |
| Week 3 | $0.1893 | $0.2232 | $0.2633 | +0.23% |
| Week 4 | $0.1847 | $0.2234 | $0.2703 | +0.31% |
| Week 5 | $0.1807 | $0.2236 | $0.2766 | +0.39% |
| Week 6 | $0.1772 | $0.2237 | $0.2825 | +0.47% |
| Week 7 | $0.174 | $0.2239 | $0.2881 | +0.55% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Theriva Biologics, Inc., a clinical-stage healthcare company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), is a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and is in a Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications.
In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St.
Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Theriva Biologics, Inc. (TOVX) is a healthcare company with a current price of $0.2101. Its market cap is $9.64M and its current market position is ranked 4820. The stock’s near-term price trajectory appears neutral, with forecasts showing limited movement around the current level in the 2026–2029 window.
The stock trades in a 30-day price range and sits near a defined support and resistance framework that provides a reference for short-term drift.
A major floor 20.7% below — a decisive break under it would weaken the trend.
The nearest floor, 5.7% below — buyers have tended to step in here.
The nearest ceiling, 16.7% above — a clean break opens room to run.
A major ceiling 84.1% above — clearing it would confirm fresh momentum.
Key TOVX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TOVX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.212 | Buy | $0.2135 | Buy |
| MA 10 | $0.219 | Buy | $0.2186 | Buy |
| MA 20 | $0.2285 | Sell | $0.2279 | Sell |
| MA 50 | $0.2548 | Sell | $0.2477 | Sell |
| MA 100 | $0.2655 | Sell | $0.2596 | Sell |
| MA 200 | $0.2522 | Sell | $0.3909 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.42 | Neutral |
| Stoch RSI (14) | 24.78 | Neutral |
| CCI (20) | -123.95 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -12.50 | Sell |
| Bollinger %B (20,2) | 0.11 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.70 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 30.36 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | -92.00 | Sell |
| Hull MA (9) | 0.21 | Buy |
| ADX (14) | 20.52 | Sell |
| ATR (14) | 0.01 | Info |
The 30-day technical picture shows an RSI14 of 40, which is considered neutral. The price is trading below both the SMA50 at $0.256 and the SMA200 at $0.2534, indicating potential near-term pressure relative to these moving averages. The 30-day price range spans $0.1645 to $0.2683, providing a broad swing for the near term.
Support is listed at $0.21 and resistance at $0.27, offering defined levels where buyers and sellers may respond.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.18 | $0.2227 | $0.27 | 0% | Neutral | |
| $0.1686 | $0.2177 | $0.2999 | -2% | Neutral | |
| $0.1446 | $0.194 | $0.2803 | -13% | Neutral | |
| $0.1366 | $0.1892 | $0.2836 | -15% | Bearish | |
| $0.1539 | $0.2194 | $0.3389 | -2% | Neutral | |
| $0.1597 | $0.2337 | $0.3708 | +5% | Neutral | |
| $0.1761 | $0.2641 | $0.429 | +19% | Neutral | |
| $0.1847 | $0.2836 | $0.4705 | +27% | Bullish | |
| $0.1696 | $0.2661 | $0.4502 | +19% | Neutral | |
| $0.1613 | $0.2585 | $0.4454 | +16% | Neutral | |
| $0.2132 | $0.3771 | $0.7001 | +69% | Bullish | |
| $0.2408 | $0.5086 | $1.05 | +128% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $0.18 | $0.2227 | $0.2606 | +0.00% |
| September 2026 | $0.1826 | $0.2179 | $0.2686 | -2.17% |
| October 2026 | $0.1868 | $0.225 | $0.2813 | +3.26% |
| November 2026 | $0.1807 | $0.2192 | $0.2772 | -2.57% |
| December 2026 | $0.173 | $0.2113 | $0.27 | -3.59% |
Click any year to see its month-by-month TOVX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TOVX to range from $0.18 to $0.27 through 2026. The $0.2227 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The TOVX price prediction for 2027 points to an average of $0.2177 (low $0.1686, high $0.2999) — a potential decline of -2% on today's $0.2227. A consolidation phase looks the most probable path here.
In 2028, TOVX is projected to trade between $0.1446 and $0.2803, averaging $0.194 — a potential decline of -13% from today's $0.2227. That is -11% versus the projected 2027 average. Price action looks broadly range-bound.
Theriva Biologics, Inc.'s 2029 outlook centres on $0.1892, within a $0.1366 to $0.2836 range. That is -2% versus the projected 2028 average. That marks a -15% change versus current levels. Expect choppier, lower action through this leg of the cycle.
By 2030, TOVX could reach as high as $0.3389, with a base case around $0.2194 and support toward $0.1539 — roughly -2% from $0.2227. Price action looks broadly range-bound.
Expect TOVX to range from $0.1597 to $0.3708 through 2031. The $0.2337 average target implies a +5% move from current prices. That is up +7% on the projected 2030 average. A consolidation phase looks the most probable path here.
The TOVX price prediction for 2032 points to an average of $0.2641 (low $0.1761, high $0.429) — a potential gain of +19% on today's $0.2227. Price action looks broadly range-bound.
In 2033, TOVX is projected to trade between $0.1847 and $0.4705, averaging $0.2836 — a potential gain of +27% from today's $0.2227. That is up +7% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Theriva Biologics, Inc.'s 2034 outlook centres on $0.2661, within a $0.1696 to $0.4502 range. That is -6% versus the projected 2033 average. That marks a +19% change versus current levels. Price action looks broadly range-bound.
By 2035, TOVX could reach as high as $0.4454, with a base case around $0.2585 and support toward $0.1613 — roughly +16% from $0.2227. A consolidation phase looks the most probable path here.
Expect TOVX to range from $0.2132 to $0.7001 through 2040. The $0.3771 average target implies a +69% move from current prices. That is up +46% on the projected 2035 average. Momentum favours further upside here.
The TOVX price prediction for 2050 points to an average of $0.5086 (low $0.2408, high $1.05) — a potential gain of +128% on today's $0.2227. Buyers look set to stay in control over this stretch.
Investing $1,000 in TOVX today (≈ 4,490.345757 TOVX) could be worth
$2,283.73
+$1,283.73 (+128%) by 2050 · US Dollar
Based on the average projected TOVX price of $0.51 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TOVXwould be worth at today's price.
$1,000 invested in TOVX on Jul 31, 2025 (≈ 2,222.222281 TOVX) would be worth
$494.89
-$505.11 (-50.5%) today · 0.49× · US Dollar
Based on a TOVX entry price of $0.45 vs. today's $0.2227.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.22 | $1,012.27 | +1.2% |
| 1 month ago | $0.25 | $890.8 | -10.9% |
| 3 months ago | $0.39 | $571.03 | -42.9% |
| 6 months ago | $0.18 | $1,237.22 | +23.7% |
| 1 year ago | $0.45 | $494.89 | -50.5% |
| All time (5.0y) ago | $127.5 | $1.75 | -99.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TOVX forecast.
Our base-case forecast reaches $0.45 around 2050.
Implied market cap at $0.45: $20.65M
The multi-year forecast shows a path from flat or modestly higher levels in the mid-term to a more clearly bullish trajectory later in the horizon. For 2026 the avg price is $0.2101 with a min of $0.18, a max of $0.2553, and ROI of 0%; the sentiment is NEUTRAL. In 2027 the avg is $0.2064 with a min of $0.1592, a max of $0.2859, and ROI of -1.8% (NEUTRAL).
2028 shows a min of $0.1356, an avg of $0.1829, a max of $0.2659, with ROI -13% (NEUTRAL); 2029 has min $0.1295, avg $0.1806, max $0.2727, ROI -14% (NEUTRAL). The outlook improves from 2030 onward, with 2030 avg $0.2138 and ROI 1.8% (NEUTRAL); 2031 avg $0.2274, ROI 8.2%; 2032 avg $0.2574, ROI 22.5%; 2033 avg $0.2772, ROI 31.9%; 2034 avg $0.2558, ROI 21.8%; 2035 avg $0.2506, ROI 19.3% (sentiment shifts to BULLISH through 2034, then NEUTRAL in 2035). The forecast turns notably bullish in the longer horizon with 2040 avg $0.3684, ROI 75.4% (BULLISH) and 2050 avg $0.5028, ROI 139.3% (BULLISH).
These are estimates of future price levels and are not guarantees; they reflect market expectations for a range of outcomes and are subject to change.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $0.2138 with a min of $0.1488, a max of $0.3331 and ROI of 1.8%. The sentiment is NEUTRAL.
Near term shows a NEUTRAL stance with the 2026 avg at $0.2101 (ROI 0%) and 2027 at $0.2064 (ROI -1.8%), followed by further declines in 2028 and 2029. The longer horizon turns BULLISH from 2032 onward, with notable upside projected by 2040 and 2050 (ROI 75.4% and 139.3% respectively). These are forecast estimates, not guarantees.
Yes, the longer-term forecast includes a max price of $1.05 in 2050 with an avg of $0.5028 and ROI 139.3%, indicating a potential to exceed $1 in the distant horizon, though this is not guaranteed.
The 30-day range is $0.1645 to $0.2683, reflecting the near-term volatility band for the stock.
Current price is $0.2101. Market cap is $9.64M. The rank by market cap is 4820.
Theriva Biologics, Inc. Community Discussion
0Share your Theriva Biologics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.